Congestive Heart Failure

General Management Principles

- Stop smoking
- Restrict alcohol use
- Salt restriction to 2 or 3 grams of sodium per day, or less
- Weight reduction in obese members to within 10 percent of ideal body weight
- Daily weight monitoring and logging to detect fluid accumulation before it becomes symptomatic
- Review for drugs that might contribute to CHF or worsen some aspect of the condition (partial list of important drugs shown below)
  - NSAIDs – causes fluid retention
  - Aspirin – can interfere with the effects of beta-blockers
  - Cardiodepressiv e calcium channel blockers, like Verapamil
  - Thiazolidinediones – cause fluid retention
  - Metformin – required sometimes in Type II diabetics, but increase risk of lactic acidosis.
  - Cardiotoxic chemotherapeutic drugs, like Cytoxan, anthracyclines, etc. – decrease myocardial contractility
  - Tumor necrosis factor inhibitors, like infliximab – worsen CHF
  - Glucocorticosteroids – cause sodium and water retention
  - Carbamazepine – negative inotropic effect
  - Tricyclic antidepressants – negative inotropic effect
  - Itraconazole – negative inotropic effect
- Annual influenza vaccination
- Evaluate for pneumococcal vaccine of for a booster

Important Clinical Interventions

- Treat Contributing factors
  - Eliminate unneeded drugs that exacerbates CHF
  - Control elevated blood pressure
  - Correct anemia
  - Correct abnormal heart rhythms, especially atrial fibrillation.
  - Recognize and treat heart valve problems
  - Correct hypothyroidism, if present
  - If bed ridden, post-operative, or hypercoaguable state (i.e. cancer), exclude pulmonary embolus
  - Rule out superimposing infection, such a pneumonia
  - Correct electrolyte abnormalities
  - Recognize and treat renal dysfunction
  - If child-bear age female, exclude pregnancy
  - Treat and manage diabetes

- Pharmacotherapy Required
  - Angiotensin converting enzyme inhibitors (ACE inhibitors) in all CHF patients who can tolerate them, unless contraindicated
Angiotensin receptor blockers (ARBs) in CHF patients who cannot tolerate ACE inhibitors, unless contraindicated

- Diuretics and salt restriction for fluid retention
- Beta blockers in all stable patients, unless contraindicated. Especially, bisoprolol, carvedilol, and sustained-release metoprolol.
- African-American patients with moderately severe CHF may benefit from hydralazine and nitrates.
- Aldosterone antagonist for selected members with moderately severe or severe CHF who can tolerate them.
  - Creatinine should be less than 2.0 mg/dL in women and 2.5 mg/dL in men.
  - Potassium should be less than 5.0 mEq/L, and should be monitored if on ACEI or ARB.

Helpful
- Digitalis in members with poor symptom control may reduce hospitalizations
- Addition of hydralazine and nitrates to symptomatic members already taking ACEI and beta-blockers.
- Addition of ARB to members already taking ACEI, and other drugs, if uncontrolled

Other Indicated Clinical Interventions
- Exercise training in stable ambulatory members
- AICD in members with sudden cardiac arrest, ventricular fibrillation, or hemodynamically destabilizing ventricular tachycardia
- Cardiac resynchronization therapy (CRT), with or without an ICD, unless contraindicated, in patients who meet the following criteria: cardiac dyssynchrony as defined by a QRS duration >120 msec, LVEF ≤35 percent, sinus rhythm, and New York Heart Association functional class III or ambulatory class IV symptoms despite optimal medical therapy

Patient Education Issues
- Medication noncompliance
- Dietary indiscretion
- Alcohol consumption
- Tobacco and other substances abuse
- Weight monitoring
- Early symptom recognition (i.e. ankle swelling, PND, orthopnea, DOE, etc.)

ACC Guideline at http://content.onlinejacc.org/cgi/reprint/46/6/1116.pdf

2009Focused Update Incorporated into the ACC/AHA Guidelines for the diagnosis And Management of Heart Failure in Adults


References
11. Lok, CE, Morgan, CD, Ranganathan, N. The accuracy and interobserver agreement in detecting the 'gallop sounds' by cardiac auscultation. Chest 1998; 114:1283.


46. Fonarow, GC, Abraham, WT, Albert, NM, et al. Influence of beta-blocker continuation or withdrawal on outcomes in patients hospitalized with heart failure:
findings from the OPTIMIZE-HF program. J Am Coll Cardiol 2008; 52:190.